Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Net Margin (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Net Margin readings, the most recent being 1.43% for Q1 2026.

  • On a quarterly basis, Net Margin rose 109.0% to 1.43% in Q1 2026 year-over-year; TTM through Jan 2026 was 0.97%, a 422.0% increase, with the full-year FY2025 number at 1.12%, up 706.0% from a year prior.
  • Net Margin hit 1.43% in Q1 2026 for Pharma-Bio Serv, up from 0.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 11.5% in Q3 2023 to a low of 12.79% in Q3 2024.
  • Median Net Margin over the past 5 years was 1.43% (2026), compared with a mean of 0.72%.
  • The widest YoY moves for Net Margin: up 9079bps in 2022, down -3958bps in 2022.
  • Pharma-Bio Serv's Net Margin stood at 3.74% in 2022, then plummeted by -135bps to 1.31% in 2023, then soared by 153bps to 0.69% in 2024, then plummeted by -101bps to 0.0% in 2025, then surged by 30276bps to 1.43% in 2026.
  • The last three reported values for Net Margin were 1.43% (Q1 2026), 0.0% (Q4 2025), and 10.89% (Q3 2025) per Business Quant data.